Cancer Causes & Control

, Volume 24, Issue 7, pp 1459–1464 | Cite as

Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors

  • Christina B. Rasmussen
  • Mette T. Faber
  • Allan Jensen
  • Estrid Høgdall
  • Claus Høgdall
  • Jan Blaakær
  • Susanne K. Kjaer
Brief report

Abstract

Purpose

The aim of the study was to examine the potential association between a history of pelvic inflammatory disease (PID) and risk of epithelial ovarian cancer or ovarian borderline tumors.

Methods

In a population-based case–control study in Denmark, we included 554 women with invasive ovarian cancer, 202 with ovarian borderline tumors, and 1,564 controls aged 35–79 years. The analyses were performed in multiple logistic regression models.

Results

We found a significantly increased risk of ovarian borderline tumors among women with a history of PID (OR = 1.50; 95 % CI 1.08–2.08) but no apparent association between PID and risk of invasive ovarian cancer (OR = 0.83; 95 % CI 0.65–1.05). We found no effect of age at time of first PID or time since first PID on the risk for either condition.

Conclusion

Our results suggest that a history of PID is associated with an increased risk of ovarian borderline tumors, which may support the hypothesis that inflammation is an etiological factor. The lack of an association between previous PID and invasive ovarian cancer may indicate an etiological difference between ovarian borderline tumors and invasive ovarian cancer. However, an important limitation of the study is the use of self-reported PID.

Keywords

Ovarian cancer Ovarian borderline tumor Pelvic inflammatory disease Inflammation Risk factor 

References

  1. 1.
    Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2:163PubMedCrossRefGoogle Scholar
  2. 2.
    Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMedGoogle Scholar
  3. 3.
    Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467PubMedCrossRefGoogle Scholar
  4. 4.
    Shan W, Liu J (2009) Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 8:3107–3111PubMedCrossRefGoogle Scholar
  5. 5.
    Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98:1781–1783PubMedCrossRefGoogle Scholar
  6. 6.
    Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S et al (2013) Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 92:245–255PubMedCrossRefGoogle Scholar
  7. 7.
    Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ et al (2011) Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 12:900–904PubMedCrossRefGoogle Scholar
  8. 8.
    Lareau SM, Beigi RH (2008) Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am 22:693–708, viiGoogle Scholar
  9. 9.
    Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih I (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605–1614PubMedCrossRefGoogle Scholar
  10. 10.
    Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58–64PubMedCrossRefGoogle Scholar
  11. 11.
    Seidman JD, Sherman ME, Bell KA, Katabuchi H, O’Leary TJ, Kurman RJ (2002) Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol 21:101–107PubMedCrossRefGoogle Scholar
  12. 12.
    Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE et al (2000) Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111–117PubMedCrossRefGoogle Scholar
  13. 13.
    Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667–669PubMedGoogle Scholar
  14. 14.
    Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4:447–451PubMedGoogle Scholar
  15. 15.
    Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case–control study of ovarian cancer in Shanghai. Cancer Res 49:3670–3674PubMedGoogle Scholar
  16. 16.
    Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176PubMedCrossRefGoogle Scholar
  17. 17.
    Huusom LD, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK et al (2006) Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case–control study. Cancer Causes Control 17:821–829PubMedCrossRefGoogle Scholar
  18. 18.
    Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J et al (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16:1160–1166PubMedCrossRefGoogle Scholar
  19. 19.
    Crispens MA (2003) Borderline ovarian tumours: a review of the recent literature. Curr Opin Obstet Gynecol 15:39–43PubMedCrossRefGoogle Scholar
  20. 20.
    Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM et al (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case–control study. Gynecol Oncol 83:575–585PubMedCrossRefGoogle Scholar
  21. 21.
    Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218–224PubMedCrossRefGoogle Scholar
  22. 22.
    Aral SO, Mosher WD, Cates W Jr (1985) Self-reported pelvic inflammatory disease in the US: a common occurrence. Am J Public Health 75:1216–1218PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Christina B. Rasmussen
    • 1
  • Mette T. Faber
    • 1
  • Allan Jensen
    • 1
  • Estrid Høgdall
    • 1
    • 2
  • Claus Høgdall
    • 3
  • Jan Blaakær
    • 4
  • Susanne K. Kjaer
    • 1
    • 3
  1. 1.Unit of Virus, Lifestyle and GenesDanish Cancer Society Research CenterCopenhagenDenmark
  2. 2.Department of PathologyHerlev University HospitalCopenhagenDenmark
  3. 3.Department of Obstetrics and GynecologyRigshospitaletCopenhagenDenmark
  4. 4.Department of Obstetrics and GynecologySkejby University HospitalAarhusDenmark

Personalised recommendations